3 news items
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NRBO
9 May 24
for Alexander Prezioso, M.D., Investigator, Clinical Pharmacology
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NRBO
17 Apr 24
-controlled, double-blind, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
NRBO
28 Mar 24
and Drug Administration (FDA) cleared our Investigational New Drug (IND) application for the clinical trial, we received our first site Institutional
- Prev
- 1
- Next